MODULATION OF NEUORGENESIS BY HDac INHIBITION
The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on an HDac inhibitory agent alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.
1 . A method of lessening or reducing a decline or decrease of cognitive function in a subject or patient treated with anti-cancer chemotherapy and/or radiation therapy, said method comprising
administering an HDac inhibitory agent to said subject or patient to lessen or reduce a decline or decrease of cognitive function due to anti-cancer chemotherapy and/or radiation therapy.
2 . The method of claim 1 wherein said lessening or reducing results in maintenance or stabilization of cognitive function in said subject or patient.
3 . The method of claim 1 wherein said HDac inhibitory agent is administered before, or concurrent with, said anti-cancer chemotherapy and/or radiation therapy.
4 . The method of claim 1 wherein said HDac inhibitory agent is trichostatin A, apicidin, MS-275, FK228, or SAHA.
5 . The method of claim 1 wherein said chemotherapy comprises administration of a kinase inhibitor or a therapy independent of HDac inhibition.
6 . The method of claim 1 wherein said patient is a human being diagnosed as having cancer.
7 . A method of lessening or reducing a decline or decrease of cognitive function associated with epilepsy in a subject or patient, said method comprising
i) diagnosing said subject or patient as in need of lessening or reducing a decline or decrease in cognitive function associated with epilepsy, and
administering an HDac inhibitory agent to said subject or patient to lessen or reduce a decline or decrease of cognitive function in said subject or patient; or
ii) administering an HDac inhibitory agent, other than valproic acid, to said subject or patient to lessen or reduce a decline or decrease of cognitive function in said subject or patient.
8 . The method of claim 7 wherein said lessening or reducing results in maintenance or stabilization of cognitive function in said subject or patient.
9 . The method of claim 7 wherein said HDac inhibitory agent is trichostatin A, apicidin, MS-275, FK228, or SAHA.
10 . The method of claim 7 wherein said subject or patient is a human being diagnosed as having epilepsy or having seizures associated with epilepsy.
11 . A method of treating a nervous system disorder related to cellular degeneration, a psychiatric condition, cellular trauma and/or injury, or another neurologically related condition in a subject or patient, said method comprising
administering an HDac inhibitory agent, optionally in combination with another an HDac inhibitory agent and/or another neurogenic agent, to said subject or patient to produce an improvement in said disorder,
wherein said disorder is not epilepsy.
12 . The method of claim 11 , wherein said nervous system disorder related to cellular degeneration is selected from a neurodegenerative disorder, a neural stem cell disorder, a neural progenitor cell disorder, a degenerative disease of the retina, an ischemic disorder, and combinations thereof; or
wherein said nervous system disorder related to a psychiatric condition is selected from a neuropsychiatric disorder, an affective disorder, depression, hypomania, panic attacks, anxiety, excessive elation, bipolar depression, bipolar disorder (manic-depression), seasonal mood (or affective) disorder, schizophrenia and other psychoses, lissencephaly syndrome, anxiety syndromes, anxiety disorders, phobias, stress and related syndromes, cognitive function disorders, aggression, drug and alcohol abuse, obsessive compulsive behavior syndromes, borderline personality disorder, non-senile dementia, post-pain depression, post-partum depression, cerebral palsy, and combinations thereof; or
wherein said nervous system disorder related to cellular trauma and/or injury is selected from neurological traumas and injuries, surgery related trauma and/or injury, retinal injury and trauma, injury related to epilepsy, spinal cord injury, brain injury, brain surgery, trauma related brain injury, trauma related to spinal cord injury, brain injury related to cancer treatment, spinal cord injury related to cancer treatment, brain injury related to infection, brain injury related to inflammation, spinal cord injury related to infection, spinal cord injury related to inflammation, brain injury related to environmental toxin, spinal cord injury related to environmental toxin, and combinations thereof; or
wherein said neurologically related condition is selected from learning disorders, memory disorders, autism, attention deficit disorders, narcolepsy, sleep disorders, cognitive disorders, epilepsy, temporal lobe epilepsy, and combinations thereof.
13 . A method of treating a mood disorder in a subject or patient, said method comprising
administering an HDac inhibitory agent, optionally in combination with another an HDac inhibitory agent and/or another neurogenic agent, to a subject or patient that is
a) under treatment with anti-cancer chemotherapy and/or radiation therapy, or
b) diagnosed as having epilepsy or having seizures associated with epilepsy,
to produce an improvement in said mood disorder.
14 . The method of claim 13 , wherein said mood disorder is selected from depression, anxiety, hypomania, panic attacks, excessive elation, seasonal mood (or affective) disorder, schizophrenia and other psychoses, lissencephaly syndrome, anxiety syndromes, anxiety disorders, phobias, stress and related syndromes, aggression, non-senile dementia, post-pain depression, and combinations thereof.
15 . The method of claim 13 , wherein said HDac inhibitory agent is valproic acid.
16 . A method of protecting neural cells from damage or toxicity, said method comprising
contacting a population of neural cells with an HDac inhibitory agent to protect said cells.
17 . The method of claim 16 , wherein the level of differentiation of said protected cells into astrocytes is limited or inhibited.
18 . A method to maintain or reduce the differentiation of neural cells into astrocytes, said method comprising
contacting a population of neural cells with an HDac inhibitory agent to maintain or reduce their differentiation into cells of an astrocytic lineage.
19 . The method of claim 18 , wherein said cells are in a subject or patient with a nervous system disorder related to disease, cellular degeneration, a psychiatric condition, cellular trauma and/or injury, or another neurologically related condition.
20 . A method to reduce or inhibit aberrant differentiation, proliferation and/or migration of neural cells in a tissue, said method comprising
administering an HDac inhibitory agent to a subject or patient to reduce or inhibit aberrant differentiation, proliferation and/or migration of neural cells into a tissue.
21 . The method of claim 20 , wherein said subject or patient has a nervous system disorder related to disease, cellular degeneration, a psychiatric condition, cellular trauma and/or injury, or another neurologically related condition.
22 . The method of claim 16 , wherein said cells are
in a human patient or in a tissue of a human patient; optionally diagnosed with cancer, or
in a human patient treated with chemotherapy and/or radiation; or
in a human patient diagnosed as having epilepsy or having seizures associated with epilepsy.
23 . A method of preparing cells or tissue for transplantation to a subject or patient, said method comprising
contacting said cell or tissue with an HDac inhibitory agent, optionally in combination with another HDac inhibitory agent and/or another neurogenic agent, to stimulate or increase neurogenesis in said cell or tissue.
24 . A method of maintaining, stabilizing, stimulating, or increasing neurodifferentiation in a cell or tissue, said method comprising
contacting said cell or tissue with an HDac inhibitory agent to maintain, stabilize stimulate, or increase neurodifferentiation in said cell or tissue.
25 . The method of claim 24 , further comprising contacting said cell or tissue with an additional neurogenic or neuroproliferative agent to produce neurogenesis in said cell or tissue, optionally wherein said cell or tissue exhibits decreased neurogenesis or is subjected to an agent or condition which decreases or inhibits neurogenesis; or
wherein said cell or tissue is in an animal subject or a human patient, optionally wherein said subject or patient is in need of neurogenesis or has been diagnosed with a disease, condition, or injury of the central or peripheral nervous system; or
wherein said cell or tissue exhibits aberrant neurogenesis or neuroproliferation.